Glucose lowering drugs such as Glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-dependent glucose transporters 2 (SGLT2) inhibitors have shown potential protective roles in kidney diseases, and SGLT2 blockers could affect glomerular filtration rate (GFR) and protein excretion in diabetic nephropathy (DN), while GLP-1R agonists reduced urinary albumin excretion in DN [10–12]. This evidence concerns the gene GLP1R and kidney disorder.